Search results for "LIPIDE"

showing 10 items of 532 documents

Differences in cell proliferation in rodent and human hepatic derived cell lines exposed to ciprofibrate.

2005

International audience; Humans appear to be refractory to some effects of peroxisome proliferators including alterations in cell proliferation, whereas rodents are susceptible. In this study, differences between the human and rat response to peroxisome proliferators were evaluated using rat and human tumour liver cell lines. Rat 7777 cells were more responsive than human HepG2 cells to ciprofibrate as they exhibited a higher decrease in cell number than HepG2, and underwent apoptosis. Results from these studies reveal a surprising response in tumour cell lines as the typical in vivo response of increased cell proliferation and reduced apoptosis was not observed in rat tumour cell lines at c…

MESH : Cell LineCancer ResearchRodentApoptosisMESH : Dose-Response Relationship DrugCell LineClofibric AcidIn vivobiology.animalmedicineMESH : Cell ProliferationAnimals[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyCell ProliferationHypolipidemic AgentsDose-Response Relationship DrugbiologyCell growthMESH : RatsFibric AcidsMESH : LiverMESH : Clofibric AcidRatsCell biologyLiverOncologyApoptosisCell cultureHepg2 cellsCancer researchPeroxisome proliferator-activated receptor alphaCiprofibrateMESH : AnimalsMESH : Apoptosismedicine.drugMESH : Antilipemic Agents
researchProduct

Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess …

2020

The assessment and prevention of cardiovascular risk (CVR) that persists in patients with dyslipidaemia despite treatment and achievement of goals specific to the plasma concentration of cholesterol linked to low density (c-LDL) is a clinical challenge today, and suggests that conventional lipid biomarkers are insufficient for an accurate assessment of CVR. Apart from their lipid content, there are other lipid particle characteristics. The results of this study show that there are a number of lipoprotein compounds that determine atherogenic potential and its influence on the CVR. However, such additional characteristics cannot be analysed by the techniques commonly used in clinical laborato…

Magnetic Resonance SpectroscopyLipoproteinsDiseasechemistry.chemical_compoundNuclear magnetic resonanceDiabetes mellitusHumansMedicineDyslipidemiasGeneral Environmental Sciencebusiness.industryCholesterolGeneral EngineeringLipid metabolismArteriosclerosisAtherosclerosismedicine.diseaseLipidschemistryCardiovascular DiseasesHeart Disease Risk FactorsSpainGeneral Earth and Planetary Scienceslipids (amino acids peptides and proteins)Lipid particleMetabolic syndromebusinessLipoproteinClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment

2018

In recent years, obesity and metabolic syndrome (MetS) have become a growing problem for public health and clinical practice, given their increased prevalence due to the rise of sedentary lifestyles and unhealthy eating habits. Thanks to animal models, basic research can investigate the mechanisms underlying pathological processes such as MetS. Here, we describe the methods used to develop an experimental rabbit model of diet-induced MetS and its assessment. After a period of acclimation, animals are fed a high-fat (10% hydrogenated coconut oil and 5% lard), high-sucrose (15% sucrose dissolved in water) diet for 28 weeks. During this period, several experimental procedures were performed to…

Male0301 basic medicineGeneral Chemical EngineeringPhysiologyDisease030204 cardiovascular system & hematologyDiet High-FatGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineAnimalsPathologicalMetabolic Syndrome030109 nutrition & dieteticsGeneral Immunology and MicrobiologyTriglyceridebusiness.industryExperimental modelGeneral NeuroscienceModels Theoreticalmedicine.diseaseObesityDisease Models AnimalBlood pressurechemistryMedicineRabbitsMetabolic syndromebusinessDyslipidemiaJournal of Visualized Experiments
researchProduct

Homozygous Familial Hypercholesterolemia in Spain Prevalence and Phenotype-Genotype Relationship

2016

Background— Homozygous familial hypercholesterolemia (HoFH) is a rare disease characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and extremely high risk of premature atherosclerotic cardiovascular disease. HoFH is caused by mutations in several genes, including LDL receptor ( LDLR ), apolipoprotein B ( APOB ), proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), and LDL protein receptor adaptor 1 ( LDLRAP1 ). No epidemiological studies have assessed HoFH prevalence or the clinical and molecular characteristics of this condition. Here, we aimed to characterize HoFH in Spain. Methods and Results— Data were collected from the Spanish Dyslipidemia Regist…

Male0301 basic medicineOncologyLdl receptor geneApolipoprotein BLipid-lowering therapyFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosity0302 clinical medicineAutosomal-dominant hypercholesterolemiaRisk FactorsEpidemiologyPrevalenceDiseaseRegistriesGenetics (clinical)Molecular EpidemiologybiologyhypercholesterolemiaHomozygoteDouble-blindMiddle AgedPhenotypeCardiovascular DiseasesApolipoprotein B-100allelesFemalelipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineMutationsAdultGenetic MarkersHeterozygotemedicine.medical_specialtyInhibitorAdolescentPlacebo-controlled trialHyperlipoproteinemia Type IIlipidsYoung Adult03 medical and health sciencesInternal medicineGeneticsmedicineHumansGenetic Predisposition to DiseaseAlleleAdaptor Proteins Signal TransducingRecessive hypercholesterolemiaPCSK9registriesCholesterol LDLApolipoprotein-bmedicine.disease030104 developmental biologyEndocrinologyReceptors LDLSpainMutationLDL receptorbiology.proteinmutationDyslipidemia
researchProduct

CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db mice

2018

Abstract Aims CD40 ligand (CD40L) signaling controls vascular oxidative stress and related dysfunction in angiotensin-II-induced arterial hypertension by regulating vascular immune cell recruitment and platelet activation. Here we investigated the role of CD40L in experimental hyperlipidemia. Methods and results Male wild type and CD40L−/− mice (C57BL/6 background) were subjected to high fat diet for sixteen weeks. Weight, cholesterol, HDL, and LDL levels, endothelial function (isometric tension recording), oxidative stress (NADPH oxidase expression, dihydroethidium fluorescence) and inflammatory parameters (inducible nitric oxide synthase, interleukin-6 expression) were assessed. CD40L exp…

Male0301 basic medicinePhysiologyAnti-Inflammatory AgentsNitric Oxide Synthase Type II030204 cardiovascular system & hematologyWeight Gainmedicine.disease_causeAntioxidantschemistry.chemical_compound0302 clinical medicineHyperlipidemiaEndothelial dysfunctionMice KnockoutbiologyLeptinLipidsVasodilationNitric oxide synthaseInflammation Mediatorsmedicine.symptomCardiology and Cardiovascular Medicinemedicine.medical_specialtyCD40 LigandHyperlipidemiasInflammationDiet High-Fat03 medical and health sciencesPhysiology (medical)Internal medicinemedicineAnimalsHumansObesityPlatelet activationInflammationTNF Receptor-Associated Factor 6Interleukin-6Cholesterolbusiness.industryMyocardiumNADPH OxidasesPlatelet Activationmedicine.diseaseMice Inbred C57BLDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2chemistrybiology.proteinEndothelium VascularbusinessBiomarkersOxidative stressCardiovascular Research
researchProduct

Lipidomic profiling identifies signatures of metabolic risk

2020

Background: Metabolic syndrome (MetS), the clustering of metabolic risk factors, is associated with cardiovascular disease risk. We sought to determine if dysregulation of the lipidome may contribute to metabolic risk factors. Methods: We measured 154 circulating lipid species in 658 participants from the Framingham Heart Study (FHS) using liquid chromatography-tandem mass spectrometry and tested for associations with obesity, dysglycemia, and dyslipidemia. Independent external validation was sought in three independent cohorts. Follow-up data from the FHS were used to test for lipid metabolites associated with longitudinal changes in metabolic risk factors. Results: Thirty-nine lipids were…

Male0301 basic medicineResearch paperdhSL dihydrosphingolipidBMI body mass indexlcsh:MedicineATHEROGENIC LIPOPROTEINSBioinformaticsFHS Framingham Heart StudyPC phosphatidylcholinePESA Progression of Early Subclinical Atherosclerosis0302 clinical medicineFramingham Heart StudyRisk FactorsSAFHS San Antonio Family Heart StudyLC-MS/MS liquid chromatography-tandem mass spectrometryMedicineLongitudinal StudiesMetabolic riskPLASMA SPHINGOLIPID METABOLISMPOPULATIONlcsh:R5-920education.field_of_studySPHINGOMYELINCE cholesteryl esterDysglycemiaGeneral MedicineMiddle AgedLipidomePS phosphatidylserineCardiovascular diseaseLipidsMetabolic syndrome3. Good healthCARDIOVASCULAR-DISEASE030220 oncology & carcinogenesisHEARTMetS metabolic syndromeFemaleDisease SusceptibilityLGPL lysoglycerophospholipidSL sphingolipidlcsh:Medicine (General)LPE lysophosphatidylethanolamineAdultFDR false discovery rateTAG triacylglycerolPopulationCer ceramideCVD cardiovascular diseasePE phosphatidylethanolamineDENSITY-LIPOPROTEINRisk AssessmentGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAnimalsHumanseducationT2DM type II diabetes mellitusAgedLPC lysophosphatidylcholineSM sphingomyelinbusiness.industryCERAMIDElcsh:RHDL-C High density lipoprotein cholesterolBiomarkerLipid Metabolismmedicine.diseaseObesitySphingolipidCross-Sectional Studies030104 developmental biologyDyslipidemiaERF Erasmus Family StudyLipidomicsMetabolic syndromeINDUCED INSULIN-RESISTANCEbusinessDAG diacylglycerolBody mass indexBiomarkersDyslipidemiaMRM multiple reaction monitoringFASTING GLUCOSE
researchProduct

Hyperlipidaemia prevalence and cholesterol control in obstructive sleep apnoea: Data from the European sleep apnea database (ESADA)

2019

Abstract.Gunduz C, Basoglu OK, Hedner J, et al; onbehalf of the European Sleep Apnoea Databasecollaborators (Biruni University; Ege University;Gothenburg University; Sahlgrenska UniversityHospital; University of Palermo; CNR Institute ofBiomedicine and Molecular Immunology; St. AdolfStift; Hospital de Santa Maria; University of Crete;Antoine-Beclere Hospital; G. PapanikolaouHospital; Institute of Tuberculosis and LungDiseases; University Hospital Brno; St. Ann’sUniversity Hospital; Universite ́ Grenoble Alpes)Hyperlipidaemia prevalence and cholesterolcontrol in obstructive sleep apnoea: Data from theEuropean sleep apnea database (ESADA).J InternMed2019;286: 676–688.Background and objective.…

Male0301 basic medicine[SDV]Life Sciences [q-bio]PolysomnographyHyperlipidemiasSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologycomputer.software_genre03 medical and health sciences0302 clinical medicineRisk FactorsDiabetes mellitusPrevalenceInternal MedicineHumansMedicinecholesterol ; hyperlipidaemia ; hypoxia ; obesity ; sleep apnoea.ObesitySleep Apnea ObstructiveDatabasehyperlipidaemiahypoxiabusiness.industryConfoundingcholesterolSleep apneaOdds ratioMiddle Agedmedicine.diseaseObesityrespiratory tract diseases[SDV] Life Sciences [q-bio]EuropeCross-Sectional Studies030104 developmental biologyQuartileCardiovascular DiseasesCohortFemaleHuman medicinebusinesssleep apnoeaBody mass indexcomputer
researchProduct

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

2017

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance®), ameliorates glucotoxicity via excretion of excess glucose in urine (glucosuria) and significantly improves cardiovascular mortality in type 2 diabetes mellitus (T2DM). The overarching hypothesis is that hyperglycemia and glucotoxicity are upstream of all other complications seen in diabetes. The aim of this study was to investigate effects of empagliflozin on glucotoxicity, β-cell function, inflammation, oxidative stress and endothel…

Male0301 basic medicineendocrine system diseasesDiabetic CardiomyopathiesFPS-ZM1 RAGE inhibitorClinical BiochemistryAorta ThoracicRAGE receptor for AGEICAM-1 intercellular adhesion molecule-1ECL enhanced chemiluminescence030204 cardiovascular system & hematologyDPP-4 dipeptidyl peptidase-4medicine.disease_causeTNF-α tumor necrosis factor-αBiochemistryeNOS endothelial •NO synthase (type 3)0302 clinical medicineGlucosidesecSOD extracellular superoxide dismutaseInsulin-Secreting CellsCCL-2 see MCP-1HyperlipidemiaHyperinsulinemiaGTN glyceryl trinitrate (nitroglycerin)IFN-γ interferon-γDHE dihydroethidineEndothelial dysfunctionEndothelial dysfunctionIL-6 interleukin-6lcsh:QH301-705.5HO-1 heme oxygenase-1lcsh:R5-920ICAM-1NG normoglycemiaDiabetesNox catalytic subunit of NADPH oxidaseSGLT2 inhibitorβ-cell contentL-012 8-amino-5-chloro-7-phenylpyrido[34-d]pyridazine-14-(2H3H)dione sodium saltChIP chromatin immunoprecipitationC-Reactive ProteinCRP C-reactive proteinAGE advanced glycation end productsHbA1c glycohemoglobinlcsh:Medicine (General)Research PaperZucker diabetic fatty ratsmedicine.medical_specialtyDMSO dimethylsulfoxideMCP-1 monocyte-chemoattractant-protein-1qRT-PCR quantitative reverse transcription polymerase chain reactionZDF Zucker diabetic fatty (rat)Low-grade inflammation03 medical and health sciencesROS reactive oxygen speciesSodium-Glucose Transporter 2Physiology (medical)Internal medicineDiabetes mellitusPKC protein kinase CEmpagliflozinmedicineAnimalsHypoglycemic AgentsBenzhydryl CompoundsCOX2 cyclooxygenase-2SGLT2i SGLT2 inhibitorSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinACh acetylcholinebusiness.industryOrganic Chemistrynutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseH2K9me2 histone3 lysine9 dimethylationRatsRats ZuckerDHFR dihydrofolate reductaseSGLT2 sodium-glucose co-transporter-2Oxidative StresssGC soluable guanylyl cyclaseGlucose030104 developmental biologyEndocrinologylcsh:Biology (General)ALDH-2 mitochondrial aldehyde dehydrogenaseEndothelium VascularAGE/RAGE signalingHG hyperglycemiabusinessOxidative stressRedox Biology
researchProduct

Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high fat diet

2016

Previous studies suggested that endogenous glucagon-like peptide 2 (GLP-2) is dispensable for the regulation of glucose homeostasis under normal conditions, while it can play a beneficial role in obesity conditions. The purpose of the present study was to investigate whether chronic treatment with Gly2-GLP-2, a stable analogue of GLP-2, can have an impact on glycaemic and lipid control in mice fed a high-fat diet (HFD), an animal model of human obesity and insulin resistance. HFD mice were treated once a day with Gly2-GLP-2 for 4 weeks. Body weight, food intake, fasting glucose, intraperitoneal glucose tolerance, insulin-induced glucose clearance, glucose-stimulated insulin secretion, β-cel…

Male0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDrug Evaluation PreclinicalMicrovesicular SteatosisCarbohydrate metabolismDiet High-FatSettore BIO/09 - FisiologiaRandom Allocation03 medical and health sciencesEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusGlucagon-Like Peptide 2medicineAnimalsGlucose homeostasisObesityPancreasPancreatic islets.Glucose Metabolism Disordersbusiness.industrydigestive oral and skin physiologyInsulin resistancemedicine.diseaseGlucagon-like peptide-2LipidsObesityMice Inbred C57BL030104 developmental biologyEndocrinologyLiverPeptidesbusinessGLP-2Dyslipidemia
researchProduct

Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver

1992

AbstractThe process of peroxisome proliferation in rodent liver by hypolipidemic compounds and related substances has recently been shown to be receptor-madiated. In the present study, we have examined the effect of oral administration of the strong peroxisome proliferator fenofibrate on the hepatic expression level of the peroxisome proliferator activated receptor (PPAR) in rats. Immunoblots of rat liver cytosols and nuclear extracs using antibodies raised against recombinant PPAR/β-galactosidase fusion proteins revealed a pronounced increase in the amount of PPAR protein in response to fenofibrate treatment. This induction could also be confirmed at the level or RNA by Northern blotting. …

Male1303 BiochemistryReceptors Cytoplasmic and Nuclear10050 Institute of Pharmacology and ToxicologyPeroxisome proliferator-activated receptorPPARMicrobodiesPolymerase Chain ReactionBiochemistryPPAR agonist1307 Cell BiologyMiceCytosol1315 Structural BiologyFenofibrateStructural Biologychemistry.chemical_classificationMice Inbred BALB CFenofibrateOligodeoxyribonucleotidesPeroxisome proliferator-activated receptor alphaFusion proteinmedicine.drugmedicine.medical_specialtyPeroxisome proliferator-activated receptor gammamRNAMolecular Sequence DataBiophysicsPeroxisome ProliferationReceptors Cell Surface610 Medicine & healthBiology1311 GeneticsInternal medicine1312 Molecular BiologyGeneticsmedicineAnimalsNorthern blotMolecular BiologyAntibodyHypolipidemic compoundCell NucleusMessenger RNABase SequenceImmune SeraCell BiologyBlotting NorthernRatsMice Inbred C57BLEndocrinologychemistry570 Life sciences; biologyTranscription Factors1304 BiophysicsFEBS Letters
researchProduct